Market capitalization | $7.55m |
Enterprise Value | $-12.10m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.48 |
P/B ratio (TTM) P/B ratio | 0.34 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-20.14m |
Free Cash Flow (TTM) Free Cash Flow | $-25.16m |
Cash position | $19.68m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Galecto Inc:
1 Analyst has issued a forecast Galecto Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.46 -0.46 |
40%
40%
|
|
EBITDA | -20 -20 |
55%
55%
|
EBIT (Operating Income) EBIT | -20 -20 |
54%
54%
|
Net Profit | -21 -21 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.
Head office | United States |
CEO | Hans Schambye |
Employees | 13 |
Founded | 2011 |
Website | www.galecto.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.